The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
Christian S ThudiumAnne C Bay-JensenSuntara CahyaErnst R DowMorten A KarsdalAlisa E KochWenling ZhangRobert J BenschopPublished in: Arthritis research & therapy (2020)
ClinicalTrials.gov NCT01721057 ; date of registration: November 1, 2012.